Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Cancer Radiother ; 25(1): 45-50, 2021 Feb.
Article in French | MEDLINE | ID: mdl-33402288

ABSTRACT

PURPOSE: The annual follow-up in radiotherapy for prostate cancer consists of an oral interview with a radiation oncologist. The present study aimed at surveying the target population on their knowledge and perceptions of telemedicine. MATERIALS AND METHODS: A prospective study was conducted at the Lucien Neuwirth Cancer Institute (France) that included patients with prostate cancer undergoing treatment or in follow-up, during spring 2019 (n=158). A specific questionnaire was designed for the study. Patient's self-evaluation of satisfaction and enthusiasm was assessed through visual analog scale (VAS) (0/10 to 10/10). RESULTS: One hundred and fifty-eight patients completed the survey. The vast majority of the population commonly used phone for communication and 56% of patients owned internet connexion. Around 56% of patients declared telemedicine knowledge without having ever experienced telemedicine. If 60.8% of patients would not be against telemedicine with a median enthusiasm VAS of 6/10, patients' opinions were divergent: 48.7% of patients would like to keep a classical follow-up and 48.7% of patients would envision to alternate classical consultation with telemedicine. CONCLUSION: This feasibility study with an aged cohort showed that telemedicine is a valuable option for long-term radiotherapy follow-up, even if therapeutic education and information will be necessary to supervise this novel approach.


Subject(s)
Health Knowledge, Attitudes, Practice , Prostatic Neoplasms/radiotherapy , Telemedicine/statistics & numerical data , Aged , Aged, 80 and over , Feasibility Studies , Follow-Up Studies , Humans , Internet/statistics & numerical data , Male , Middle Aged , Prospective Studies , Surveys and Questionnaires/statistics & numerical data , Telephone/statistics & numerical data
2.
Cancer Radiother ; 24(1): 15-20, 2020 Feb.
Article in French | MEDLINE | ID: mdl-31983629

ABSTRACT

PURPOSE: Patients frequently report asthenia during radiation. The present study aimed at identifying the correlation between numerous clinical and tumoral factors and asthenia in breast and prostate cancer patients treated by curative radiotherapy. MATERIALS AND METHODS: A retrospective study was conducted at the Lucien Neuwirth Cancer Institute (France). All breast and prostate cancer patients undergoing curative radiotherapy during 2015 were screened (n=806). Patient's self-evaluation of asthenia and radiotherapy tolerance was assessed through verbal analogic scale (0/10 to 10/10). Data about toxicities, travel distance and travel time, tumor's characteristics, radiotherapy treatment planning, previous cancer therapies, were collected from medical records. RESULTS: 500 patients were included (350 in the breast cancer group and 150 in the prostate cancer group). In all, 86% of patients in the breast cancer group reported asthenia, with a 5/10 median score. In all, 54% of patients in the prostate cancer group reported asthenia, with a 2/10 median score. Univariate analysis showed correlation between asthenia and radiotherapy tolerance as well as tumor staging, in the prostate cancer group. No other correlation was evidenced. CONCLUSION: Radiotherapy-related fatigue is a common side effect. This study showed that most of the factors related to patients or disease that are commonly used to explain fatigue during curative treatments, seem finally to be not correlated with asthenia.


Subject(s)
Asthenia/etiology , Breast Neoplasms/radiotherapy , Prostatic Neoplasms/radiotherapy , Aged , Aged, 80 and over , Breast Neoplasms/pathology , Female , France , Humans , Male , Middle Aged , Prostatic Neoplasms/pathology , Radiotherapy/adverse effects , Retrospective Studies
3.
Curr Res Transl Med ; 66(4): 111-113, 2018 11.
Article in English | MEDLINE | ID: mdl-30097215

ABSTRACT

Deciphering the mutational patterns and/or the biomarkers that might predict clinical response in patients with myelofibrosis is primordial to make treatment decisions. In this report, we discuss the clinical history, pathological evaluation, and genomics findings in a patient with JAK2-positive myelofibrosis who developed a secondary myelodysplasia after hematopoietic stem cell transplantation and JAK1/2 inhibitor treatment. Using next-generation sequencing, a paired comparison of relapse-specific versus primary tumour mutations highlighted the dynamic clonal evolution at relapse, showing concurrently the complete eradication of the JAK2-positive clone and the expansion of a second JAK2-negative clone with additional mutations. Importantly, another unexpected finding was that myelodysplasia was not secondary to allogeneic transplantation as relapse was driven by the overgrowth of a preexisting mutated clone, probably fostered by initial treatment options. This case underlines the fact that determining the genetic changes associated with the primary disease and its evolution is crucial to accurately correlate variants frequency to treatment decision and/or treatment response.


Subject(s)
Clonal Evolution , Graft vs Host Disease/drug therapy , Hematopoietic Stem Cell Transplantation/adverse effects , Primary Myelofibrosis/therapy , Pyrazoles/therapeutic use , Chronic Disease , Clonal Evolution/drug effects , Female , Graft vs Host Disease/etiology , Graft vs Host Disease/pathology , Humans , Middle Aged , Nitriles , Primary Myelofibrosis/pathology , Pyrimidines , Transplantation, Homologous/adverse effects
5.
Curr Res Transl Med ; 66(4): 107-110, 2018 11.
Article in English | MEDLINE | ID: mdl-29519713

ABSTRACT

AIM: SOS/VOD is a relevant clinical syndrome that usually appears early after hematopoietic stem cell transplantation. The purpose of this article was to report a case series of SOS/VOD in non-susceptible patients and draw physicians' attention to the plausible relationship between liver injury and oxaliplatin-based chemotherapy, preceding autologous transplantation. METHODS: In this study, we report a case series of SOS/VOD in 4 lymphoma patients following autologous transplantation. The data were collected between July 2013 and November 2015 by analyzing patient's characteristics and outcomes. RESULTS: We noticed 4 severe cases of SOS with unusual presentations in patients who did exhibit few classical risk factors. These patients received R-DHAO before transplantation. CONCLUSIONS: Physicians need to be aware that oxaliplatin-based regimen could contribute to SOS/VOD complications in hematological patients.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Hematopoietic Stem Cell Transplantation/adverse effects , Hepatic Veno-Occlusive Disease/etiology , Lymphoma/therapy , Oxaliplatin/administration & dosage , Aged , Combined Modality Therapy , Female , Hepatic Veno-Occlusive Disease/diagnosis , Humans , Lymphoma/complications , Lymphoma/drug therapy , Male , Middle Aged , Oxaliplatin/adverse effects , Transplantation, Autologous
6.
Oncogene ; 33(31): 4050-9, 2014 Jul 31.
Article in English | MEDLINE | ID: mdl-24141782

ABSTRACT

MMP-11 is a bad prognosis paracrine factor in invasive breast cancers. However, its mammary physiological function remains largely unknown. In the present study we have investigated MMP-11 function during postnatal mammary gland development and function using MMP-11-deficient (MMP-11-/-) mice. Histological and immunohistochemical analyses as well as whole-mount mammary gland staining show alteration of the mammary gland in the absence of MMP-11, where ductal tree, alveolar structures and milk production are reduced. Moreover, a series of transplantation experiments allowed us to demonstrate that MMP-11 exerts an essential local paracrine function that favors mammary gland branching and epithelial cell outgrowth and invasion through adjacent connective tissues. Indeed, MMP-11-/- cleared fat pads are not permissive for wild-type epithelium development, whereas MMP-11-/- epithelium transplants grow normally when implanted in wild-type cleared fat pads. In addition, using primary mammary epithelial organoids, we show in vitro that this MMP-11 pro-branching effect is not direct, suggesting that MMP-11 acts via production/release of stroma-associated soluble factor(s). Finally, the lack of MMP-11 leads to decreased periductal collagen content, suggesting that MMP-11 has a role in collagen homeostasis. Thus, local stromal MMP-11 might also regulate mammary epithelial cell behavior mechanically by promoting extracellular matrix stiffness. Collectively, the present data indicate that MMP-11 is a paracrine factor involved during postnatal mammary gland morphogenesis, and support the concept that the stroma strongly impact epithelial cell behavior. Interestingly, stromal MMP-11 has previously been reported to favor malignant epithelial cell survival and promote cancer aggressiveness. Thus, MMP-11 has a paracrine function during mammary gland development that might be harnessed to promote tumor progression, exposing a new link between development and malignancy.


Subject(s)
Extracellular Matrix/metabolism , Mammary Glands, Animal/cytology , Mammary Glands, Animal/growth & development , Matrix Metalloproteinase 11/metabolism , Paracrine Communication , Stromal Cells/cytology , Animals , Animals, Newborn , Cell Differentiation/physiology , Cells, Cultured , Epithelial Cells/cytology , Female , Gene Expression Regulation, Developmental , Humans , Mice , Mice, Knockout , NIH 3T3 Cells
SELECTION OF CITATIONS
SEARCH DETAIL
...